NASDAQ · RADX
Radiopharm Theranostics Limited
Healthcare · Biotechnology
$1.52
Down-$0.49 (-24.38%)
Updated Sep 16, 2026, 10:03 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.24M
- P/E ratio
- 0
- Dividend yield
- 0.00%
- 52-week range
- $1.97 – $16.25
- Volume
- 164.33K
- Avg. volume
- 26.17K
Price performance
RADX price history
1M range · 20 trading sessions · Daily adjusted prices
RADX closed at $1.52 after 20 trading sessions, down 41.98% for the selected period.
- Last close
- $1.52
- Period change
- -41.98%
- Period low
- $1.52
- Period high
- $2.62
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.00 | $2.00 | $1.50 | $1.52 | 164.33K |
| Sep 14, 2026 | $2.01 | $2.075 | $1.97 | $2.01 | 58.51K |
| Sep 11, 2026 | $2.06 | $2.0875 | $1.98 | $1.98 | 37.6K |
| Sep 10, 2026 | $2.11 | $2.28 | $2.05 | $2.06 | 21.99K |
| Sep 9, 2026 | $2.15 | $2.4699 | $2.05 | $2.08 | 74.07K |
| Sep 8, 2026 | $2.08 | $2.2965 | $2.06 | $2.12 | 27.67K |
| Sep 4, 2026 | $2.05 | $2.145 | $2.05 | $2.08 | 7.91K |
| Sep 3, 2026 | $2.06 | $2.23 | $2.05 | $2.155 | 18.72K |
| Sep 2, 2026 | $2.27 | $2.30 | $2.05 | $2.16 | 11.01K |
| Sep 1, 2026 | $2.27 | $2.27 | $2.18 | $2.27 | 14.58K |
| Aug 31, 2026 | $2.37 | $2.4421 | $2.185 | $2.28 | 49.62K |
| Aug 28, 2026 | $2.46 | $2.7215 | $2.27 | $2.41 | 334.03K |
| Aug 27, 2026 | $2.18 | $2.327 | $2.0437 | $2.26 | 106.8K |
| Aug 26, 2026 | $2.427 | $2.53 | $2.32 | $2.32 | 21.67K |
| Aug 25, 2026 | $2.42 | $2.537 | $2.34 | $2.48 | 34.85K |
| Aug 24, 2026 | $2.43 | $2.52 | $2.35 | $2.44 | 73.07K |
| Aug 21, 2026 | $2.355 | $2.5216 | $2.30 | $2.44 | 48.85K |
| Aug 20, 2026 | $2.45 | $2.45 | $2.23 | $2.29 | 88.94K |
| Aug 19, 2026 | $2.65 | $2.7084 | $2.45 | $2.50 | 93.09K |
| Aug 18, 2026 | $2.66 | $2.79 | $2.5501 | $2.62 | 39.47K |
Latest RADX news
The latest Smart Investors Daily articles mentioning RADX.
Stock researchCompany · Overview
RADX research
Overview
Company profile and research snapshot.
Company profile
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | JONES TRADING | Buy | — |
| Jan 31, 2026 | JONES TRADING | Buy | — |
| Dec 17, 2025 | JONES TRADING | Buy | — |
| Dec 16, 2025 | JONES TRADING | Buy | — |
| Dec 16, 2025 | BELL POTTER SECURITIES | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
